1McMahon BJ,Alward WL,Hall DB,et al.Acute hepatitis B virus infection:relation of age to the clinical expression of disease and subsequent development of the carrier state[].The Journal of Infectious Diseases.1985
2EASL International Consensus Conference on Hepatitis B.13-14September,2002Geneva,Switzerland.Consensus statement(long version)[].Journal of Hepatology.2003
3Yang H,Westlang CE,Delaney WE,et al.Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to60weeks[].Hepatology.2002
4Marcellin P,Chang TT,Lim SG et al.Adefovir dipivoxil for the treatment of hepatitis B antigenpositive chronic hepatitis B[].The New England Journal of Medicine.2003
5Hadziyannis SJ,Tassopoulos NC,Heathcote EJ,et al.Adefovir dipivoxil for the treatment of hepatitis B antigen-negative chronic hepatitis B[].The New England Journal of Medicine.2003
6Schiff ER,Lai Cl,Hadziyannis S et al.Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre-and post-liver transplantation patients[].Hepatology.2003
2Wang CH,Cheng XM,Blight SW,et al.Pharmacokinetics and bioavailability of gentiopicroside from decoctions of Gentianae and Longdan Xiegan Tang after oral administration in rats-Comparison with gentiopicroside alone[J].J Pharmaceut Biomed,2007,44(5):1 113-1 117.
3Filburn CR,Kettenacker R,Griffin DW,et al.Bioavailability of a silybin-phosphatidylcholine complex in dogs[J].J Vet Pharmacol Ther,2007,30(2):132-138.
